LRRK2 and Microtubules

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease (PD). LRRK2 mutations in PD have been shown to enhance its association with microtubules. Here is the latest research.

January 23, 2020
Open Access

Molecular mechanism for the recognition of sequence-divergent CIF peptides by the plant receptor kinases GSO1/SGN3 and GSO2

Proceedings of the National Academy of Sciences of the United States of America
Satohiro OkudaMichael Hothorn
February 5, 2020
Open Access

Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2

Structure
Dieter WaschbuschAmir R. Khan
January 8, 2020
Open Access

Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson's Disease through Activating Mitophagy

Antioxidants
Ming-Wei LinShih-Ya Hung
April 11, 2020
Review
Open Access

Origins of Parkinson's Disease in Brain Development: Insights From Early and Persistent Effects of LRRK2-G2019S on Striatal Circuits

Frontiers in Neuroscience
George W Huntley, Deanna L Benson
November 10, 2019
Preprint
Open Access

The in situ structure of Parkinson's disease-linked LRRK2

BioRxiv : the Preprint Server for Biology
Reika WatanabeElizabeth Villa
December 10, 2019
Open Access

miR-185 and SEPT5 Genes May Contribute to Parkinson's Disease Pathophysiology

Oxidative Medicine and Cellular Longevity
Arman RahimmiKambiz Hassanzadeh
October 30, 2019
Open Access

The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

Movement Disorders : Official Journal of the Movement Disorder Society
Sara Bandres-CigaInternational Parkinson Disease Genomics Consortium
February 13, 2020
Open Access

Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models

Current Protocols in Neuroscience
Mikko AiravaaraAndrii Domanskyi
March 19, 2020
Open Access

The NLR-Annotator Tool Enables Annotation of the Intracellular Immune Receptor Repertoire

Plant Physiology
Burkhard SteuernagelBrande B H Wulff
February 13, 2020

Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present)

Expert Opinion on Therapeutic Patents
Xiao Ding, Feng Ren
January 4, 2020
Preprint
Open Access

Pathway-specific deregulation of striatal excitatory synapses in LRRK2 mutations

BioRxiv : the Preprint Server for Biology
Chuyu ChenLoukia Parisiadou
October 13, 2019
Open Access

The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo

Neurobiology of Disease
Noémie CrestoEmmanuel Brouillet
April 6, 2020

Prodromal PD: A new nosological entity

Progress in Brain Research
Eva SchaefferDaniela Berg
December 23, 2019
Review
Open Access

LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same

Molecular Neurodegeneration
Daniel C BerwickKirsten Harvey
January 24, 2020
Preprint
Open Access

LRRK2 mediates tubulation and vesicle sorting from membrane damaged lysosomes

BioRxiv : the Preprint Server for Biology
Luis Bonet-PonceMark R Cookson
September 12, 2019
Preprint
Open Access

PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2 mediated phosphorylation at Threonine72

BioRxiv : the Preprint Server for Biology
Sophie ViewegMiratul Muqit
January 1, 2020
Open Access

Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinson's Disease Patients

Journal of Clinical Medicine
Clara Berenguer-EscuderRejko Krüger
July 14, 2020
Preprint
Open Access

Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2

BioRxiv : the Preprint Server for Biology
S. H. SchmidtSusan S. Taylor

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/lrrk2-and-microtubules/e1132ba7-7a6a-494b-8f07-c617e7d85d2a